Dyslipidemia and dementia: Current epidemiology, genetic evidence, and mechanisms behind the associations

Journal of Alzheimer's Disease

Volumn 30, Issue SUPPL.2, 2012, Pages

  Reitz, Christiane ^a,b  

^a Department of Epidemiology   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Alzheimer's disease; amyloid; amyloid peptides; amyloid protein precursor; cholesterol; genetics; neurodegeneration

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER A2; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BETA SECRETASE; CAVEOLIN 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; GAMMA SECRETASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE LIPID; SORTILIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAU PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ALZHEIMER DISEASE; APOPTOSIS; BIOSYNTHESIS; BRAIN; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME ACTIVITY; EXOCYTOSIS; FOLLOW UP; GENE PRODUCT; GENETIC LINKAGE; HUMAN; HUNTINGTON CHOREA; METABOLIC SYNDROME X; METABOLITE; MULTIPLE SCLEROSIS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863006444     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110599     Document Type: Review

References (178)

1. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342. (Pubitemid 28402270)
2. von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L (1999) Aging and the occurrence of dementia: Findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol 56, 587-592. (Pubitemid 29218154)
3. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
4. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA (2006) Vascular risk factors for incident Alzheimer disease and vascular dementia: The Cache County study. Alzheimer Dis Assoc Disord 20, 93-100. (Pubitemid 44305908)
5. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hal-likainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
6. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissi-nen A (2005) Obesity and vascular risk factorsat midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560. (Pubitemid 41434560)
7. Li G, Shofer JB, Kukull WA, Peskind ER, TsuangDW, Breit-ner JC, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB (2005) Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. Neurology 65, 1045-1050. (Pubitemid 41429629)
8. Mainous AG, 3rd, Eschenbach SL, Wells BJ, Everett CJ, Gill JM (2005) Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: Results from an 18-year population-based cohort. Fam Med 37, 36-42. (Pubitemid 40094090)
9. Romas SN, Tang MX, Berglund L, Mayeux R (1999) APOE genotype, plasma lipids, lipoproteins, andADin community elderly. Neurology 53, 517-521. (Pubitemid 29382044)
10. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D'Agostino RB, WolfPA (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease: The framingham study. Arch Intern Med 163, 1053-1057. (Pubitemid 36548931)
11. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehn-holm C, Kivinen P, Tuomilehto J, Nissinen A (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17, 14-20. (Pubitemid 28153361)
12. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors andriskofdemen-tia in late life. Neurology 64, 277-281.
13. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, Skoog I (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64, 1689-1695. (Pubitemid 40695799)
14. Reitz C, Tang MX, Luchsinger J, Mayeux R (2004) Relation of plasma lipidstoAlzheimer disease andvascular dementia. Arch Neurol 61, 705-714. (Pubitemid 38637688)
15. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M (1997) Associationbetween featuresofthe insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 315, 1045-1049. (Pubitemid 27458392)
16. Stewart R, White LR, Xue QL, Launer LJ (2007) Twenty-six-year change in total cholesterol levels and incident dementia: The Honolulu-Asia Aging Study. Arch Neurol64, 103-107. (Pubitemid 46072431)
17. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Bey-doun HA, Ferrucci L, Resnick SM, Zonderman AB (2011) Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health, doi: 2010;jech.2009.100826.
18. Trkanjec Z, Bene R, Martinic-Popovic I, Jurasic JM, Lisak M, Seric V, Demarin V (2009) Serum HDL, LDL and total cholesterol in patients with late-life onset of Alzheimer's disease versus vascular dementia. Acta Clin Croat 48, 259-263.
19. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 67, 1491-1497.
20. Solfrizzi V, Scafato E, Capurso C, D'Introno A, Colacicco AM, Frisardi V, Vendemiale G, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Capurso A, Panza F (2010) Metabolic syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 81, 433-440.
21. Reynolds CA, Gatz M, Prince JA, Berg S, Pedersen NL (2010) Serum lipid levels and cognitive change in late life. J Am Geriatr Soc 58, 501-509.
22. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petro-vitch H, Ross GW, Havlik RJ, Launer LJ (2000) Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20, 2255-2260.
23. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H (2006) Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba. Neurology 66, 223-227. (Pubitemid 43970158)
24. Michikawa M (2003) Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 72, 141-146. (Pubitemid 36389880)
25. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378-384. (Pubitemid 34208144)
26. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, Stern Y, Mayeux R (1999) Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282, 254-260. (Pubitemid 29343168)
27. Furberg CD (1999) Natural statins and stroke risk. Circulation 99, 185-188. (Pubitemid 29056354)
28. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB (2010) Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 58, 1311-1317.
29. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.
30. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. Neurology 64, 1531-1538. (Pubitemid 40617688)
31. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
32. Horsdal HT, Olesen AV, Gasse C, Sorensen HT, Green RC, Johnsen SP (2009) Use of statins and risk of hospitaliza-tion with dementia: A Danish population-based case-control study. Alzheimer Dis Assoc Disord 23, 18-22.
33. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H (2008) The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe) : Design and baseline characteristics. Alzheimers Dement 4, 145-153.
34. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
35. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257, 85-90.
36. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7-22.
37. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipopro-tein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185, 3-7. (Pubitemid 44015218)
38. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER) : A randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
39. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59, 223-227. (Pubitemid 34240938)
40. Grziwa B, Grimm MO, Masters CL, Beyreuther K, Hartmann T, Lichtenthaler SF (2003) The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J Biol Chem 278, 6803-6808. (Pubitemid 36800669)
41. Pfrieger FW (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 60, 1158-1171. (Pubitemid 36791918)
42. Arnaud C, Mach F (2005) Pleiotropic effects of statins in atherosclerosis: Role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98, 661-666.
43. Jurevics H, Morell P (1995) Cholesterol for synthesis of myelinismade locally, not imported into brain.J Neurochem 64, 895-901.
44. Fagan AM, Holtzman DM (2000) Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc Res Tech 50, 297-304. (Pubitemid 30651170)
45. Poirier J (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9, 94-101.
46. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45, 186-193. (Pubitemid 38180529)
47. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36, 27-32. (Pubitemid 34037845)
48. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lann-felt L, Winblad B, Russell DW, Bjorkhem I (2001) On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314, 45-48. (Pubitemid 33043802)
49. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Bjorkhem I, von Bergmann K, Heun R (2000) Plasma 24S- hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 11, 1959-1962.
50. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8, 890-899. (Pubitemid 33055603)
51. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
52. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathwaybyits effect onthe alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98, 5815-5820. (Pubitemid 32435725)
53. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460-6464. (Pubitemid 28249035)
54. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE (2002) Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neuro- biol Dis 9, 11-23. (Pubitemid 34174561)
55. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M (2003) Amyloid beta protein (Abeta) 1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87, 609-619. (Pubitemid 37310627)
56. McLaurin J, Darabie AA, Morrison MR (2003) Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis. Pharmacopsychiatry 36 (Suppl 2) , S130-S135.
57. Trousson A, Bernard S, Petit PX, Liere P, Pianos A, El Hadri K, Lobaccaro JM, Ghandour MS, Raymondjean M, Schumacher M, Massaad C (2009) 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J Neurochem 109, 945-958.
58. Ma MT, Zhang J, Farooqui AA, Chen P, Ong WY (2010) Effects of cholesterol oxidation products on exocytosis. Neurosci Lett 476, 36-41.
59. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262, 14352-14360. (Pubitemid 17152101)
60. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357. (Pubitemid 33063104)
61. Eto M, Watanabe K, Chonan N, Ishii K (1988) Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72, 123-128.
62. Murakami K, Shimizu M, Yamada N, Ishibashi S, Shimano H, Yazaki Y, Akanuma Y (1993) Apolipoprotein E polymorphism is associated with plasma cholesterol response in a 7-day hospitalization study for metabolic and dietary control in NIDDM. Diabetes Care 16, 564-569. (Pubitemid 23097201)
63. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
64. Graff-Radford NR, Green RC, Go RC, Hutton ML, Edeki T, Bachman D, Adamson JL, Griffith P, Willis FB, Williams M, Hipps Y, Haines JL, Cupples LA, Farrer LA (2002) Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 59, 594-600. (Pubitemid 34289963)
65. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E geno type, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study. Neurology 45, 1092-1096.
66. Rubinsztein DC, Easton DF (1999) Apolipoprotein E genetic variation and Alzheimer's disease. A meta-analysis. Dement Geriatr Cogn Disord 10, 199-209. (Pubitemid 29224496)
67. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB (1998) Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51, 149-153. (Pubitemid 28345375)
68. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 6820-6825.
69. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38, 254-259.
70. Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O (2010) Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol 119, 555-566.
71. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC (1998) A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet 7, 533-540. (Pubitemid 28120646)
72. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muh leisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
73. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tav-ernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Pic-cardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
74. Gelissen IC, Hochgrebe T, Wilson MR, Easterbrook-Smith SB, Jessup W, Dean RT, Brown AJ (1998) Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: A potential anti-atherogenic function? Biochem J 331 (Pt 1) , 231-237. (Pubitemid 28163979)
75. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, HoltzmanDM (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41, 193-202. (Pubitemid 38125181)
76. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteinsEandJinthe mouse central nervous system. J Cereb Blood Flow Metab 27, 909-918. (Pubitemid 46659038)
77. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR (2007) The extracellular chaper-one clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21, 2312-2322. (Pubitemid 47230661)
78. Matsubara E, Frangione B, Ghiso J (1995) Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 270, 7563-7567.
79. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39, 168-177. (Pubitemid 46184347)
80. Lee JH, Cheng R, Honig LS, Vonsattel JP, Clark L, Mayeux R (2008) Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology 70, 887-889. (Pubitemid 351367519)
81. Lee JH, Chulikavit M, Pang D, Zigman WB, Silverman W, Schupf N (2007) Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Neurosci Lett 425, 105-109. (Pubitemid 47410369)
82. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K (2008) SORL1 is genetically associated with increased risk for late-onset Alzheimer diseaseinthe Belgian population.Hum Mutat 29, 769-770.
83. Cuenco KT, Lunetta KL, Baldwin CT, McKee AC, Guo J, Cupples LA, Green RC, St George-Hyslop PH, Chui H, DeCarli C, Farrer LA (2008) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease.Arch Neurol 65, 1640-1648.
84. Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ (2006) LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol 65, 866-872. (Pubitemid 44371232)
85. Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, Younkin SG, Bu G, Estus S (2009) Expression of SORL1 and a novel SORL1 splice variantinnormal and Alzheimer's disease brain. Mol Neurodegener 4, 46.
86. Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, Takeda M (2009) SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett 461, 177-180.
87. Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, Frolich L, Heuser I, Peters O, Schulz JB, Schwab SG, Maier W (2008) Influence of SORL1 gene variants: Association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett 440, 68-71.
88. Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frolich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hull M, Kurz A, Ruther E, Henn FA, Maier W (2009) Association of SORL1 gene variants with Alzheimer's disease. Brain Res 1264, 1-6.
89. Lee JH, Barral S, Reitz C (2008) The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. Curr Neurol Neurosci Rep 8, 384-391.
90. Lee JH, Shibata N, Cheng R, Mayeux R (2008) Possible association between SORL1 and Alzheimer disease? Reanalysing the data of Shibata et al. Dement Geriatr Cogn Disor 26, 482.
91. Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'Donovan MC, Goate A, Owen M, Williams J, Grupe A (2008) SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis 29, 293-296.
92. Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM (2009) Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch Neurol 66, 448-457.
93. Meng Y, Lee JH, Cheng R, St George-Hyslop P, Mayeux R, Farrer LA (2007) Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport 18, 1761-1764. (Pubitemid 350303747)
94. Reynolds CA, Hong MG, Eriksson UK, Blennow K, Johansson B, Malmberg B, Berg S, Gatz M, Pedersen NL, Bennet AM, Prince JA (2009) Sequence variation in SORL1 and dementia risk in Swedes. Neurogenetics 11, 139-142.
95. Shibata N, Ohnuma T, Baba H, Higashi S, Nishioka K, Arai H (2008) Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population. Dement Geriatr Cogn Disord 26, 161-164.
96. Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL (2009) SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging 30, 1048-1051.
97. Webster JA, Myers AJ, Pearson JV, Craig DW, Hu-Lince D, Coon KD, Zismann VL, Beach T, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Huentelman MJ, Joshipura K, Walker D, Heward CB, Ravid R, Rogers J, Papassotiropoulos A, Hardy J, Reiman EM, Stephan DA (2008) Sorl1as an Alzheimer's disease predisposition gene? Neurodegener Dis 5, 60-64.
98. Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, Bettens K, Sleegers K, Tan EK, Kimura R, Shibata N, Arai H, Kamboh MI, Prince JA, Maier W, Riemenschneider M, Owen M, Harold D, Hollingworth P, Cellini E, Sorbi S, Nacmias B, Takeda M, Pericak-Vance MA, Haines JL, Younkin S, Williams J, van Broeckhoven C, Farrer LA, St George-Hyslop PH, Mayeux R (2011) Meta-analysis of the Association Between Variants in SORL1 and Alzheimer Disease. Arch Neurol 68, 99-106.
99. Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R (2008) Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: Implication of additional loci. Arch Neurol 65, 1518-1526.
100. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R (1998) TheAPOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279, 751-755. (Pubitemid 28114999)
101. Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M, Kase CS, D'Agostino RB Sr, Decarli C, Atwood LD, Wolf PA (2007) Genetic correlates of brain aging on MRI and cognitive test measures: A genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet 8, S15.
102. Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN, Palotas A, Lantigua R, Medrano M, I, Var-darajan ZJ-V, Simkin B, Haines I, Pericak-Vance JL, Farrer MA, Lee LA, Rogaeva JH, George-Hyslop E, Mayeux PS, R (2011) SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol 69, 47-64.
103. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632-644.
104. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunck-ley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bry-den L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papas-sotiropoulos A, Stephan DA (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54, 713-720. (Pubitemid 46843528)
105. Cheng D, Huang R, Lanham IS, Cathcart HM, Howard M, Corder EH, Poduslo SE (2005) Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J Med Genet 42, 129-131. (Pubitemid 40204366)
106. Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, Simpson JF, Tucker HM, Kelly JF, Younkin SG, Dickson DW, Petersen RC, Graff-Radford NR, Bennett DA, Crook JE, Estus S (2008) Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing effi-ciencyin the brain and Alzheimer's disease.Hum Mol Genet 17, 929-935. (Pubitemid 351426027)
107. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, Estus S (2005) Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26, 1-7. (Pubitemid 39600585)
108. Lamsa R, Helisalmi S, Herukka SK, Tapiola T, Pirttila T, Vepsalainen S, Hiltunen M, Soininen H (2008) Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Neurobiol Aging 29, 848-855. (Pubitemid 351618342)
109. Papassotiropoulos A, Lambert JC, Wavrant-De Vrieze F, Wollmer MA, von der Kammer H, Streffer JR, Maddalena A, Huynh KD, Wolleb S, Lutjohann D, Schneider B, Thal DR, Grimaldi LM, Tsolaki M, Kapaki E, Ravid R, Koni-etzko U, Hegi T, Pasch T, Jung H, Braak H, Amouyel P, Rogaev EI, Hardy J, Hock C, Nitsch RM (2005) Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegener Dis 2, 233-241. (Pubitemid 43805906)
110. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, Nitsch RM, Hock C (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66, 940-947. (Pubitemid 41032839)
111. Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ, Meyer J, Cambien F, Tiret L (2003) Com-mongenetic variationofthecholesteryl ester transfer protein gene strongly predicts future cardiovascular deathinpatients with coronary artery disease. J Am Coll Cardiol 41, 1983-1989. (Pubitemid 36677119)
112. Atzmon G, Rincon M, Rabizadeh P, Barzilai N (2005) Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev 126, 341-345. (Pubitemid 40038355)
113. Rodriguez E, Mateo I, Infante J, Llorca J, Berciano J, Com-barros O (2006) Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. J Neurol 253, 181-185. (Pubitemid 43255888)
114. Arias-Vasquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, van Duijn CM (2007) The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8, 189-193. (Pubitemid 47051013)
115. Koldamova R, Staufenbiel M, Lefterov I (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280, 43224-43235. (Pubitemid 43049289)
116. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, HoltzmanDM (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280, 43236-43242. (Pubitemid 43049290)
117. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM (2004) ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279, 40987-40993. (Pubitemid 39287699)
118. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovi-dou V, Hegi T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24, 421-426. (Pubitemid 36205049)
119. Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, Brookes AJ, Blennow K, Kehoe PG, Prince JA (2004) Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat 23, 358-367. (Pubitemid 38461517)
120. Sundar PD, Feingold E, Minster RL, DeKosky ST, Kam-boh MI (2007) Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol Aging 28, 856-862. (Pubitemid 46589738)
121. Reynolds CA, Hong MG, Eriksson UK, Blennow K, Bennet AM, Johansson B, Malmberg B, Berg S, Wiklund F, Gatz M, Pedersen NL, Prince JA (2009) A survey of ABCA1 sequence variation confirms association with dementia. Hum Mutat 30, 1348-1354.
122. Wavrant-De Vrieze F, Compton D, Womick M, Arepalli S, Adighibe O, Li L, Perez-Tur J, Hardy J (2007) ABCA1 polymorphisms and Alzheimer's disease.Neurosci Lett 416, 180-183. (Pubitemid 46437425)
123. Shibata N, Kawarai T, Lee JH, Lee HS, Shibata E, Sato C, Liang Y, Duara R, Mayeux RP, St George-Hyslop PH, Rogaeva E (2006) Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease. Neurosci Lett 391, 142-146. (Pubitemid 41736188)
124. Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, Genin B, Fournel R, Roche S, Haussy G, Massey F, Soubigou S, Brefort G, Benoit P, Brice A, Campion D, Hollis M, Pradier L, Benavides J, Deleuze JF (2005) ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol Dis 18, 119-125. (Pubitemid 40092902)
125. Wollmer MA, Kapaki E, Hersberger M, Muntwyler J, Brunner F, Tsolaki M, Akatsu H, Kosaka K, Michikawa M, Molyva D, Paraskevas GP, Lutjohann D, von Eckardstein A, Hock C, Nitsch RM, Papassotiropoulos A (2006) Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 141B, 534-536. (Pubitemid 44024448)
126. Minster RL, DeKosky ST, Kamboh MI (2009) No association of DAPK1 and ABCA2 SNPs on chromosome 9 with Alzheimer's disease. Neurobiol Aging 30, 1890-1891.
127. Wollmer MA, Sleegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, Brunner F, Huynh KD, Kilander L, Brundin RM, Hedlund M, Giedraitis V, Glaser A, Engelborghs S, De Deyn PP, Kapaki E, Tsolaki M, Daniili-dou M, Molyva D, Paraskevas GP, Thal DR, Barcikowska M, Kuznicki J, Lannfelt L, Van Broeckhoven C, Nitsch RM, Hock C, Papassotiropoulos A (2007) Association study of cholesterol-related genes in Alzheimer's disease. Neuroge-netics 8, 179-188. (Pubitemid 47051011)
128. Tansley GH, Burgess BL, Bryan MT, Su Y, Hirsch-Reinshagen V, Pearce J, Chan JY, Wilkinson A, Evans J, Naus KE, McIsaac S, Bromley K, Song W, Yang HC, Wang N, DeMattos RB, Wellington CL (2007) The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J Lipid Res 48, 1022-1034. (Pubitemid 46708669)
129. Kim WS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup W, Hill AF, Garner B (2007) Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem 282, 2851-2861. (Pubitemid 47084333)
130. Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, Stukas S, Theroux L, Chan JY, Donkin J, Wilkinson A, Balik D, Christie B, Poirier J, Lutjohann D, Demattos RB, Wellington CL (2008) ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J Lipid Res 49, 1254-1267.
131. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H (2005) APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 58, 436-441. (Pubitemid 41266630)
132. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS (2001) Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40, 3553-3560. (Pubitemid 32242812)
133. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, Fryer JD, Wahrle S, Bales KR, Paul SM, Holtzman DM (2004) ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165, 1413-1422. (Pubitemid 39297745)
134. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L (1997) Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease.Neurosci Lett230, 151-154. (Pubitemid 27342188)
135. Merched A, Xia Y, Papadopoulou A, Siest G, Visvikis S (1998) Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neurosci Lett 242, 117-119. (Pubitemid 28083006)
136. Ji Y, Urakami K, Adachi Y, Nakashima K (1999) No association between apolipoprotein A-IV codon 360 mutation and late-onset Alzheimer's disease in the Japanese population. Dement Geriatr Cogn Disord 10, 473-475. (Pubitemid 29512014)
137. Schellenberg GD, Deeb SS, Boehnke M, Bryant EM, Martin GM, Lampe TH, Bird TD (1987) Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J Neurogenet 4, 97-108. (Pubitemid 17050015)
138. Zarif Yeganeh M, Mirabzadeh A, Khorram Khorshid HR, Kamali K, Heshmati Y, Gozalpour E, Veissy K, Olad Nabi M, Najmabadi H, Ohadi M (2010) Novel extreme homozygote haplotypes at the human caveolin 1 gene upstream purine complex in sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 153B, 347-349.
139. Kang MJ, Chung YH, Hwang CI, Murata M, Fujimoto T, Mook-JungIH, Cha CI, ParkWY (2006) Caveolin-1 upregu-lation in senescent neurons alters amyloid precursor protein processing. Exp Mol Med 38, 126-133. (Pubitemid 43764733)
140. Gaudreault SB, Dea D, Poirier J (2004) Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiol Aging 25, 753-759. (Pubitemid 38698250)
141. Taguchi K, Yamagata HD, Zhong W, Kamino K, Akatsu H, Hata R, Yamamoto T, Kosaka K, Takeda M, Kondo I, Miki T (2005) Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann Neurol 57, 585-588. (Pubitemid 40471174)
142. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW (2002) A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 277, 47373-47379. (Pubitemid 36163374)
143. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160, 101-112. (Pubitemid 34052271)
144. Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, Benraiss A, Delacourte A, Bougneres P, Aubourg P, Cartier N (2010) Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology beforeorafter the onsetofamyloid plaques in mouse models of Alzheimer's disease. Mol Ther 18, 44-53.
145. Borroni B, Archetti S, Agosti C, Akkawi N, Brambilla C, Caimi L, Caltagirone C, Di Luca M, Padovani A (2004) Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators. Neurobiol Aging 25, 747-751. (Pubitemid 38698249)
146. Chalmers KA, Culpan D, Kehoe PG, Wilcock GK, Hughes A, Love S (2004) APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. Neuroreport 15, 95-98. (Pubitemid 41614979)
147. Combarros O, Infante J, Llorca J, Berciano J (2004) Genetic association of CYP46 and risk for Alzheimer's disease. Dement Geriatr Cogn Disord 18, 257-260. (Pubitemid 39370300)
148. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ML, Maier W, Heun R (2002) Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 7, 899-902.
149. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM (2000) The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegener-ation and oxidative stress. J Neurosci 20, 7345-7352.
150. Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH (2006) The roleofseladin-1/DHCR24in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25, 432-443. (Pubitemid 43152863)
151. Porcellini E, Calabrese E, Guerini F, Govoni M, Chiap-pelli M, Tumini E, Morgan K, Chappell S, Kalsheker N, Franceschi M, Licastro F (2007) The hydroxy- methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neurosci Lett 416, 66-70. (Pubitemid 46437283)
152. Rodriguez-Rodriguez E, Mateo I, Infante J, Llorca J, Garcia-Gorostiaga I, Vazquez-Higuera JL, Sanchez-Juan P, Berciano J, Combarros O (2009) Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Res 1280, 166-171.
153. Zhu H, Taylor JW, Bennett DA, Younkin SG, Estus S (2008) Lack of association of hepatic lipase polymorphisms with late-onset Alzheimer's disease. Neurobiol Aging 29, 793-794. (Pubitemid 351400821)
154. Baum L, Wiebusch H, Pang CP (2000) Roles for lipoprotein lipase in Alzheimer's disease: An association study. Microsc Res Tech 50, 291-296. (Pubitemid 30651169)
155. Blain JF, Aumont N, Theroux L, Dea D, Poirier J (2006) A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology. Eur J Neurosci 24, 1245-1251. (Pubitemid 44401648)
156. Scacchi R, Gambina G, Broggio E, Moretto G, Ruggeri M, Corbo RM (2004) The H+ allele of the lipoprotein lipase (LPL) HindIII intronic polymorphism and the risk for sporadic late-onset Alzheimer's disease. Neurosci Lett 367, 177-180. (Pubitemid 39141221)
157. Chalmers KA, Barker R, Passmore PA, Panza F, Seripa D, Solfrizzi V, Love S, Prince JA, Kehoe PG (2010) LRP-1 variation is not associated with risk of Alzheimer's disease. Int J Mol Epidemiol Genet 1, 104-113.
158. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neu-rol Disord Drug Targets 8, 16-30.
159. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, ZlokovicBV (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031. (Pubitemid 47517512)
160. Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K, Pietrzik CU (2008) LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol Dis 31, 188-197.
161. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein Eand cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66-78. (Pubitemid 47484175)
162. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LM, Lutjo-hann D, Thal D, von Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) Genetic association of acyl-coenzymeA:Cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol Psychiatry 8, 635-638. (Pubitemid 36898022)
163. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Bere-zovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM (2001) Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3, 905-912. (Pubitemid 32952255)
164. Huttunen HJ, Greco C, Kovacs DM (2007) Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 581, 1688-1692. (Pubitemid 46546584)
165. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY (2010) ACAT1 gene ablation increases 24 (S) -hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A 107, 3081-3086.
166. Spell C, Kolsch H, Lutjohann D, Kerksiek A, Hentschel F, Damian M, von Bergmann K, Rao ML, Maier W, Heun R (2004) SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele. Dement Geriatr Cogn Disord 18, 245-249. (Pubitemid 39370298)
167. Brookes AJ, Howell WM, Woodburn K, Johnstone EC, Carothers A (1997) Presenilin-I, presenilin-II, and VLDL-R associations in early onset Alzheimer's disease. Lancet 350, 336-337. (Pubitemid 27351120)
168. Helbecque N, Richard F, Cottel D, Neuman E, Guez D, Amouyel P (1998) The very low density lipoprotein (VLDL) receptor is a genetic susceptibility factor for Alzheimer disease in a European Caucasian population. Alzheimer Dis Assoc Disord 12, 368-371. (Pubitemid 29050753)
169. McIlroy SP, Vahidassr MD, Savage DA, Patterson CC, Law-son JT, Passmore AP (1999) Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 88, 140-144. (Pubitemid 29156451)
170. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H, Oyanagi K, Mizusawa H, Kanazawa I, Tsuji S (1995) Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 11, 207-209.
171. Yamanaka H, Kamimura K, Tanahashi H, Takahashi K, Asada T, Tabira T (1998) Genetic risk factors in Japanese Alzheimer's disease patients: Alpha1-ACT, VLDLR, and ApoE. Neurobiol Aging 19, S43-S46. (Pubitemid 28178937)
172. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC (2001) Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet 105, 332-342. (Pubitemid 32578230)
173. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuin-ness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Ruther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 5, e13950.
174. Luchsinger JA (2010) Diabetes, related conditions, and dementia. J Neurol Sci 299, 35-38.
175. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F (2010) Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9, 399-417.
176. Panza F, Frisardi V, Seripa D, Imbimbo BP, Sancarlo D, D'Onofrio G, Addante F, Paris F, Pilotto A, Solfrizzi V (2011) Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 8, 492-509.
177. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol 67, 835-841.
178. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76, 1485-1491.